1,226 results on '"Barohn, Richard"'
Search Results
102. The Correlation Between Static Fatigue Testing and the Quantitative Myasthenia Gravis Score and Activities of Daily Living Profile
103. A Randomized Clinical Trial of Thymectomy for the Treatment of Myasthenia Gravis
104. What's in This Issue?
105. Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy
106. Health related quality of life in young, steroid-naïve boys with Duchenne muscular dystrophy
107. EFFICACY OF PREDNISONE FOR THE TREATMENT OF OCULAR MYASTHENIA (EPITOME): A RANDOMIZED, CONTROLLED TRIAL
108. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine
109. A secondary analysis of PAIN‐CONTRoLS: Pain's impact on sleep, fatigue, and activities of daily living.
110. Contributors
111. Peripheral Neuropathies
112. Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis
113. Building a Bridge for Batten Disease
114. Neuromuscular Review Course 2021
115. Message From The Muscle Study Group Chair
116. Message From The Founding Facilitator
117. Phase II Study of Arimoclomol in IBM FDA-OOPD
118. Comparative Effectiveness of Intravenous Immunoglobulin (IVIg) and Subcutaneous Immunoglobulin (SCIg) versus Historical controls in Management of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
119. Vol 2 Issue 3 Message from the Founding Facilitator
120. Remembering Dr. Patricia Bath for Women’s History Month: Ophthalmologist, inventor and humanitarian with many firsts
121. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
122. A Phonetic Complexity-Based Approach For Intelligibility and Articulatory Precision Testing: A Preliminary Study on Talkers With Amyotrophic Lateral Sclerosis
123. New insights into B cell and T cell contributions to myasthenia gravis immune dysregulation: 31
124. Chronic Inflammatory Demyelinating Polyneuropathy
125. Guillain-Barré Syndrome
126. Inclusion Body Myositis
127. Tocilizumab is safe and tolerable and reduces C‐reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients
128. IMAJN and RRNMF Neuromuscular Journal
129. The Early History of Arimoclomol for Inclusion Body Myositis
130. Letter from the Founding Facilitator, v.2:2
131. Percy Lavon Julian PhD- The Man Who Wouldn’t Give Up
132. Episodic ataxia type 1: clinical characterization, quality of life and genotype–phenotype correlation
133. Predictors of Clinical Improvement in Rituximab-Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis
134. Abstracts from the ASENT 2008 Annual Meeting March 6–8, 2008
135. Books to Read Before You Graduate High School
136. A Patient Activities of Daily Living Scale for Amyotrophic Lateral Sclerosis
137. The Pioneering Work of Vivien Thomas
138. The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis
139. Whole-genome analysis of sporadic amyotrophic lateral sclerosis
140. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
141. Exacerbation Rate in Generalized Myasthenia Gravis and Its Predictors
142. Letter from the Founding Facilitator
143. Rick's North American Art Museum Ranking List
144. Reflex Sympathetic Dystrophy Due to Peripheral Neuropathy and the Three-Phase Bone Scan
145. The clinical spectrum of primary lateral sclerosis
146. Current concepts and controversy in chronic inflammatory demyelinating polyneuropathy
147. Diseases of the Neuromuscular Junction
148. Contributors
149. High-Dosage Ascorbic Acid Treatment in Charcot-Marie-Tooth Disease Type 1A: Results of a Randomized, Double-Masked, Controlled Trial
150. Non-dystrophic myotonia: prospective study of objective and patient reported outcomes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.